Other Pharmaceuticals - France

France

Highlights

The revenue of the Other Pharmaceuticals market in France is expected to reach US$11.39bn in 2024.
It is projected to grow at an annual growth rate (CAGR 2024-2029) of 3.28%, resulting in a market volume of US$13.38bn by 2029.
In comparison to other countries, United States is projected to generate the highest revenue of US$260.50bn in 2024.
France's pharmaceutical market is experiencing a surge in demand for alternative medicines and herbal remedies.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Pharmaceuticals market in France has been experiencing steady growth in recent years.

Customer preferences: Customers in France have shown a preference for alternative and complementary medicines, leading to an increase in demand for Other Pharmaceuticals. Additionally, the aging population in France has contributed to the growth of the market, as older individuals tend to require more pharmaceutical products.

Trends in the market: One of the major trends in the Other Pharmaceuticals market in France is the increasing demand for natural and organic products. Customers are becoming more health-conscious and are seeking out products that are perceived to be safer and more sustainable. This trend has led to the development of new products and the expansion of existing product lines to include more natural and organic options.Another trend in the market is the increasing use of e-commerce platforms to purchase pharmaceutical products. This trend has been driven by the convenience and accessibility of online shopping, as well as the availability of a wider range of products online.

Local special circumstances: France has a highly regulated pharmaceutical market, with strict rules and regulations governing the sale and distribution of pharmaceutical products. This has led to a highly competitive market, with many companies vying for market share.

Underlying macroeconomic factors: The French economy has been growing steadily in recent years, which has contributed to the growth of the Other Pharmaceuticals market. Additionally, the French government has been investing in healthcare infrastructure and services, which has further boosted demand for pharmaceutical products.In conclusion, the Other Pharmaceuticals market in France is experiencing steady growth, driven by customer preferences for alternative and complementary medicines, an aging population, and increasing demand for natural and organic products. The market is highly competitive due to strict regulations, but the growing economy and government investment in healthcare are expected to continue driving growth in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.